PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
Based on a clinical study BCIRG 001 (Martin M., Mackey J., Pienkowski T.) and as an outcome of Markov simulation it was determined that the use of 6DAC for adjuvant therapy in 10 year horizon of research allows to increase the disease-free survival by 6,09%, and overall survival by 5,88% comparing t...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
IRBIS LLC
2015-03-01
|
| coleção: | Фармакоэкономика |
| Assuntos: | |
| Acesso em linha: | https://www.pharmacoeconomics.ru/jour/article/view/79 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|